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Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent inherited 
nephropathy, with an estimated prevalence of 1 to 1000. The disease is characterized by the 
development of multiple cysts from all nephron segments leading to the enlargement of both 
kidneys and replacement of normal parenchyma (1, for review). Total kidney volume is the 
strongest predictor of renal function decline in ADPKD (2). Glomerular filtration rate (GFR) 
remains preserved up to age 40 in most patients, because glomerular hyperfiltration in 
functioning nephrons compensates for the ongoing loss of renal tissue, until end-stage renal 
failure ensues in more than 50% of patients, usually in their 5th decade.  Mutations in the PKD1 
gene account for ~85% of the affected families, whereas the remaining cases are caused by 
mutations in PKD2. PKD1 encodes polycystin-1, an integral membrane protein with a large 
extracellular domain that probably functions as a receptor and/or an adhesion molecule, whereas 
PKD2 encodes polycystin-2, a non-selective cation channel belonging to the family of transient 
receptor potential (TRP) channels. The polycystins interact to form a mechanosensory complex 
that is involved in intracellular Ca2+ homeostasis and various signalling pathways. Disruption of 
the complex leads to cyst development and enlargement resulting from tubular cell proliferation 
and transepithelial fluid secretion. The progressive understanding of these pathways has led to 
spectacular advances in the prospective treatment for ADPKD, including the blockade of 
vasopressin 2 receptor (V2R) to decrease the intracellular level of 3'-5'-cyclic adenosine 
monophosphate (cAMP) in cyst-lining tubular cells (1). 
 
Vasopressin and cAMP in ADPKD 
 The vasopressin V2 receptor is the major regulator of adenylyl cyclase activity and of 
cAMP production in the principal cells of the collecting ducts. Increased levels of cAMP and 
high expression of cAMP-target genes have been observed in the cystic kidneys of various rodent 































































models, which could arise from decreased intracellular Ca2+ concentration caused by mutations in 
polycystins 1/2, via the downregulation of phosphodiesterase PDE and stimulation of the Ca2+-
inhibitable adenylyl cyclase 6 (1). In turn, the increased production of cAMP stimulates the 
proliferation and growth of ADPKD cells and drives Cl- and fluid secretion via PKA-stimulated 
CFTR and, potentially, other transport processes located in the apical and basolateral membranes 
(3).  
The importance of the V2R-cAMP pathway has been demonstrated by the spectacular 
effects of the V2R antag nists (V2RA) OPC-31260 and Tolvaptan on lowering renal cAMP 
levels, slowing renal cyst growth and improving renal function in various models of autosomal 
recessive (PCK rat) and autosomal dominant (Pkd2WS25/- mouse) polycystic kidney disease (4). 
Similar protection has been observed when vasopressin secretion is inhibited by high water intake 
in PCK rats (5). Furthermore, the deletion of vasopressin in these PCK rats (by crossing them to 
Brattleboro rats) led to lower renal cAMP levels and an almost complete inhibition of 
cystogenesis, whereas administration of dDAVP recovered the cystic phenotype in the PCK x 
Brattleboro rats (6). Based on these preclinical studies, a phase III clinical trial investigating the 
effect of the highly-selective V2R antagonist Tolvaptan (OPC-41061) in ADPKD patients 
(TEMPO ¾) has been initiated in 2007 (7). This trial enrolled more than 1,400 ADPKD patients 
with relatively preserved kidney function (baseline estimated creatinine clearance ≥60 mL/min), 
aged 50 years or younger, and with total kidney volume ≥750 mL (MRI measurement). Blockade 
of vasopressin V2 receptor is hypothesized to inhibit cyst growth, thereby delaying ADPKD-



































































V2R antagonists in Pkd1 mice 
The aim of the TEMPO ¾ trial is to examine whether Tolvaptan at high dose is able to 
slow renal cystic progression in a preselected ADPKD population at a relatively early stage of 
disease and with a risk of progression to kidney failure. Independent of the final study outcome, 
this trial will leave important questions open, in particular the potential interest of V2RA for 
patients with more advanced disease and their efficacy at lower doses which should decrease the 
side-effects (polyuria and nycturia) and thus improve tolerance. The investigations performed in a 
Pkd1 mouse model by Meijer et al. (P XX of this issue) provide interesting insights in these 
issues (8). The study is based on the oral administration of OPC-31260 at high (0.1%) or low 
(0.05%) dose, 10 days after the specific deletion of Pkd1 in renal tubular epithelium in 11-day old 
mice (using a tamoxifen-inducible Cre system). After a 3-week or 6-week treatment (late vs. 
early intervention, respectively), the mice were sacrificed and sampled to monitor renal function 
parameters and kidney cyst growth.  
The first finding is that an early (starting at 3 weeks of age) and short-term (3 weeks) 
treatment of this Pkd1 mouse model with high dose of V2RA resulted in a significant aquaretic 
effect and attenuation of the renal cystic phenotype (estimated by relative cyst area and kidney 
weight) as compared with untreated Pkd1-deleted mice. These results confirm some of the V2RA 
effects observed in other polycystic mouse models (4), although the treatment did not ameliorate 
renal function and was not shown to lower cAMP levels and decrease the expression of target 
genes in this model (8). Secondly, the protective effect on the renal cystic phenotype is no longer 
observed after long-term (6 weeks) administration of the V2RA, even at high dose. This 
treatment escape is paralleled by a lower aquaretic response to the V2RA, as attested by less 
marked changes in the urinary volume, urinary osmolality and water intake parameters at week 6 
vs. week 3. It must be noted that the intake of V2RA remained similar between the two time 































































points, whereas the mRNA expression of V2R was significantly decreased at week 6. The third 
finding of the study is the fact that administration of V2RA at a more advanced stage of disease 
(6 weeks of age, late intervention) induced a lower aquaretic response and showed no effect on 
cyst growth. Based on these findings, the authors conclude that intervention with V2RA should 
be initiated early in the course of the disease, at high dose, and that combination therapy may be 
needed to reduce cystogenesis at a later stage. 
 
From the Pkd1 mice to ADPKD patients 
The results of Meijer et al. (8) raise several points regarding the translation of animal 
study results to human ADPKD. The discordance between encouraging preclinical studies and 
disappointing results of two clinical trials using mTOR inhibitors (9,10) has pointed to issues 
such as drug dosage, time of treatment initiation, duration of administration, choice of end-point 
and surrogate markers and, most importantly, relevance of the preclinical models used to test 
drugs and predict human outcomes (11). The mouse model used by Meijer et al. arises from the 
deletion of the Pkd1 gene (orthologous to human PKD1) in mouse. However, the kidney-specific 
loss of Pkd1 occurs at once, in the early post-natal phase, and it is segment-specific, reflecting the 
expression of Cre recombinase (8). These characteristics are very different from the two-hit 
model, which remains the most commonly accepted explanation for the focal and clonal nature of 
cystogenesis in human ADPKD (1). Elegant studies have also demonstrated that the very timing 
of Pkd1 inactivation plays a major role in the cystogenesis profile in mouse models (12). These 
factors probably explain the significant phenotype variations observed in different models. For 
instance, the Pkd1 mice used by Meijer et al. show a majority of cysts stained for uromodulin, a 
specific marker of the thick ascending limb of Henle’s loop (13), whereas only 20% of cysts, 
generally smaller, are positive for aquaporin-2 (AQP2), and no cysts positive for proximal tubule 































































markers (8). This profile is clearly distinct from what is observed in other models of Pkd1 or 
Pkd2 inactivation (14,15).  In human ADPKD, Bachinski et al. located AQP1 in a majority 
(~70%) of cysts of proximal tubule origin (gp330 positive), whereas a minority of the cysts, 
negative for AQP1 and gp330, expressed AQP2 (16). Devuyst et al. confirmed the selective and 
mutually exclusive expression of AQP1 and AQP2 in various stages of ADPKD (17). In end-
stage ADPKD, two-thirds of the cysts expressed either AQP1 or AQP2, but the two water 
channels never colocalized in the same cyst. Of note, the proportion of AQP2-positive cysts 
significantly increased with cyst size, supporting a role for vasopressin in cyst enlargement (17).  
An intriguing observation made by Meijer et al. is the decreased efficacy of the high-dose 
V2RA over time, with no significant protection observed after 6-week treatment. The authors 
show that this is not due to a lower intake of the drug (as estimated by food intake), nor to 
increased endogenous vasopressin levels (as estimated from unchanged copeptin precursor), and 
the global mRNA expression of the V2R was actually lower at this stage (8). Differences in 
pharmacokinetics and timing and/or insufficient inhibition of the V2R in this model constitute a 
potential explanation. Indeed, significant effects on renal cystogenesis and function were 
observed in the Pkd2 mouse model after 12 weeks of treatment with 0.05% OPC31260 (15). 
Alternatively, changes in down-stream effectors of vasopressin action in the collecting duct cells, 
which can be affected by polycystin-1 dosage, could also play a role (18). Finally, these findings 
may suggest that the timing of Pkd1 inactivation in this model triggers cystogenesis via 
temporally and spatially distinct pathways in different tubular segments, so that the effect of V2R 
blockage on cysts arising from the collecting ducts may only be partial and limited in time. If 
proved true, this mechanism of cystogenesis would necessitate to combine various drugs 
targeting these segment-specific pathways of cystogenesis. 































































Two final considerations should be made when extrapolating these mouse studies to man. 
First, the timing of intervention (treatment started at 3 weeks of age in the early intervention 
group) is in fact very early when considering that significant changes in renal tubular maturation 
occur up to 6 to 8 weeks of age in mouse (19,20). In man, such an early intervention would mean 
to treat young children, with potential long-term consequences due, among others, to prolonged 
polyuria (21). Second, there are species differences in the functional effect of vasopressin in the 
distal nephron (thick ascending limbs and collecting ducts), which probably sustain the much 
higher urinary concentrating capacity of the rodents as compared to man (22). Furthermore, the 
segmental distribution of the V2 receptors in mouse and human kidney remains debated (23,24). 
The effect of V2R blockade in any rodent model should thus be interpreted carefully in view of 
these potential differences.  
 
Conclusions 
Since cyst expansion is a major factor for the progressive deterioration and loss of renal 
function in ADPKD, therapies targeting fluid secretion and, thereby, cyst enlargement are of 
major clinical interest. The study of Meijer et al. provides further support for the effect of V2RA 
on slowing cyst growth in ADPKD, shown for the first time in a PKD1 orthologous model (8). 
Although this effect is not reflected by protection in terms of renal function and fibrosis in this 
model, these findings suggest that the V2RA treatment should be initiated very early in the 
disease, and with high dose inducing a strong aquaretic effect. The fact that V2RA effect is not 
sustained supports the view that cystogenesis may be a dynamic process involving different 
segments during the disease course. Moreover, these results emphasize the need for better 
characterization of disease mechanisms and species differences when considering the preclinical 
models used to investigate new therapeutic targets. 
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